Get an alert when ESTEVE PHARMACEUTICALS LTD files next

Leroy will email you the moment a new filing lands at Companies House — one short note per filing, nothing else.

Free · confirmation link first · unsubscribe in one click

Next accounts due

2026-09-30 (in 4mo)

Last filed for 2024-12-31

Confirmation statement due

2026-08-30 (in 3mo)

Last made up 2025-08-16

Watchouts

None on the register

Cash

£695K

+251.6% vs 2023

Net assets

£6M

+6.1% vs 2023

Employees

12

0% vs 2023

Profit before tax

£352K

+69.1% vs 2023

Name history

Renamed 2 times since incorporation

  1. ESTEVE PHARMACEUTICALS LTD 2021-11-15 → present
  2. INTRAPHARM LABORATORIES LIMITED 1997-08-15 → 2021-11-15
  3. TORBET HEALTHCARE LIMITED 1997-06-27 → 1997-08-15

Accounts

2-year trend · latest reflected 2024-12-31

Metric Trend 2023-12-312024-12-31
Turnover £12,321,003£14,788,058
Operating profit £181,999£318,754
Profit before tax £208,280£352,281
Net profit £208,280£352,281
Cash £197,780£695,463
Total assets less current liabilities £5,752,888£6,105,169
Net assets £5,752,888£6,105,169
Equity £5,752,888£6,105,169
Average employees 1212
Wages £844,117£1,159,196

Values shown as filed in the company's annual accounts. indicates the figure wasn't present under that line item in that period. About these numbers

Ratios

Computed from the line items above — sparklines read oldest → newest

Ratio Trend 2023-12-312024-12-31
Operating margin 1.5%2.2%
Net margin 1.7%2.4%
Return on capital employed 3.2%5.2%
Gearing (liabilities / total assets) 23.2%28.1%
Current ratio 3.94x3.20x
Interest cover 18199.90x176.30x

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Audit & accounting basis

Accounting basis
FRS 102
Reporting scope
Standalone (parent only)
Auditor
Constantin
Audit opinion
Unqualified (clean)
Going concern
Affirmed

“The financial statements are prepared on a going concern basis. The company remains assured of the financial support provided by Esteve Healthcare S.L., the ultimate controlling party. The directors have received confirmation that Esteve Healthcare S.L. will continue to support the company and provide it with adequate funds when necessary to enable it to meet its debts as they fall due in the foreseeable future. On this basis, the directors consider it appropriate to prepare the financial statements on a going concern basis.”

Group structure

  1. ESTEVE PHARMACEUTICALS LTD · parent
    1. HRA Pharma UK and Ireland Limited · UK and Ireland · specialising in rare diseases

Significant events

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

People

2 active · 17 resigned

Name Role Appointed Born Nationality
HALL, Scott Douglas Director 2025-02-17 Nov 1971 British
TOLSTRUP, Jacob Director 2025-01-15 May 1972 Danish
Show 17 resigned officers
Name Role Appointed Resigned
HODGES, Carole Mabel Secretary 1997-06-27 2003-04-16
MICHAEL, Gregory Morris Secretary 2009-05-13 2014-08-07
PATEL, Bhupendra Secretary 2003-04-16 2009-05-13
LONDON LAW SECRETARIAL LIMITED Corporate Nominee Secretary 1997-06-27 1997-06-27
DE MELLO BARRETO, Goncalo Jose Geada Director 2024-01-01 2025-01-28
HODGES, Norman Anthony Lavis Director 1997-06-27 2009-05-13
JAMES, Kevin Director 2009-05-13 2018-10-16
JUST, Rene Director 2019-01-23 2020-03-04
MICHAEL, Gregory Morris Director 2009-05-13 2014-08-07
MUNTAÑOLA PRAT, Jorge Director 2020-02-19 2025-01-15
PATEL, Bhupendra Director 2002-08-28 2009-05-13
SALZER, Uwe, Dr. Director 2016-09-01 2018-08-31
SHAFIQ, Mohammed Choudhary, Dr Director 2009-05-13 2020-09-30
VON ALVENSLEBEN, Konstantin Director 2016-06-30 2020-03-03
VON BUCHWALDT, Beatrix Director 2016-06-30 2016-08-31
WRIGHT, Philip John Director 2015-01-02 2016-01-29
LONDON LAW SERVICES LIMITED Corporate Nominee Director 1997-06-27 1997-06-27

Ownership

Persons with significant control

Name Kind Nature of control Notified Status
Mrs Montserrat Esteve Soler Individual Shares 25–50%, Voting 25–50% 2021-07-01 Ceased 2023-07-10
Riemser Pharma Uk Limited Corporate entity Shares 75–100% 2016-04-06 Ceased 2021-07-01

Filing timeline

Last 20 of 138 total filings

Material constitutional events — rename, articles re-file, resolution

  • 2025-02-07 MA Memorandum articles
  • 2025-02-07 RESOLUTIONS Resolution
  • 2024-01-08 MA Memorandum articles
  • 2024-01-08 RESOLUTIONS Resolution
Date Type Category Description
2025-10-07 AA accounts Accounts with accounts type full
2025-08-18 CS01 confirmation-statement Confirmation statement with no updates PDF
2025-02-19 AP01 officers Appoint person director company with name date PDF
2025-02-07 MA incorporation Memorandum articles
2025-02-07 RESOLUTIONS resolution Resolution
2025-02-05 TM01 officers Termination director company with name termination date PDF
2025-01-20 TM01 officers Termination director company with name termination date PDF
2025-01-17 AP01 officers Appoint person director company with name date PDF
2024-09-17 AA accounts Accounts with accounts type full
2024-08-27 CS01 confirmation-statement Confirmation statement with no updates PDF
2024-01-08 MA incorporation Memorandum articles
2024-01-08 RESOLUTIONS resolution Resolution
2024-01-02 AP01 officers Appoint person director company with name date PDF
2023-10-04 AA accounts Accounts with accounts type full
2023-08-22 CS01 confirmation-statement Confirmation statement with no updates PDF
2023-08-03 PSC08 persons-with-significant-control Notification of a person with significant control statement PDF
2023-08-03 PSC07 persons-with-significant-control Cessation of a person with significant control PDF
2022-08-25 CS01 confirmation-statement Confirmation statement with updates PDF
2022-05-19 AA accounts Accounts with accounts type full
2021-11-16 AD01 address Change registered office address company with date old address new address PDF

Public-record activity

Raw counts from Companies House — last 12–24 months

Filings
2

last 12 months

Capital events
0

last 24 months

Officers appointed
0

last 12 months

Officers resigned
0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

Year-on-year

FY2023 → FY2024 · period ending 2024-12-31 vs 2023-12-31

Each % is (latest − prior) ÷ |prior| for the line item as filed. Periods don't have to be exactly 12 months apart — a long or short period (typical around incorporation or year-end changes) will distort the comparison. Lines a company doesn't report are omitted. About these numbers

Official Companies House page